174649-03-7

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[[(phenylmethoxy)carbonyl]amino]phenyl]-, phenylmethyl ester
• CAS NO: 174649-03-7
• Molecular Formula: C26H26FN3O4
• Molecular Weight: 463.509
• Mol File: 174649-03-7.mol

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[[(phenylmethoxy)carbonyl]amino]phenyl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[[(phenylmethoxy)carbonyl]amino]phenyl]-, phenylmethyl ester(174649-03-7)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[[(phenylmethoxy)carbonyl]amino]phenyl]-, phenylmethyl ester(174649-03-7)

Safety Data

• Hazardous Substances Data: 174649-03-7(Hazardous Substances Data)

Usage

Piperazine ring

A heterocyclic compound consisting of a six-membered ring with two nitrogen atoms at positions 1 and 4.

Carboxylic acid group

A functional group consisting of a carbonyl group (C=O) and a hydroxyl group (-OH) attached to the same carbon atom.

Phenylmethyl ester group

A phenyl group (a six-membered carbon ring with a single bond to a carbon atom) attached to a methyl group (-CH3) through an ester bond (-COO-) with the carboxylic acid group.

Fluoro-substituted phenyl group

A phenyl group with a fluorine atom (F) attached as a substituent at the 2-position (ortho position) relative to the ester group.

Phenylmethoxy carbonyl amino group

A phenyl group attached to a methoxy group (-OCH3) at the para position (1-position) relative to the carbonyl group (C=O), with the nitrogen atom of the amide group (-CONH-) bonded to the phenyl ring through the carbonyl carbon.

Biological activity

The potential of the compound to interact with biological systems, such as proteins, enzymes, or receptors, which may lead to pharmacological effects.

Pharmaceutical applications

The possible use of the compound as a drug or therapeutic agent due to its biological activity and specific chemical structure.

Drug target or therapeutic agent

The compound's potential to be used as a target for drug development or as a therapeutic agent itself, based on its ability to modulate biological systems and its specific chemical structure.

Upstream product

• 154590-35-9 tert-butyl 4-(4-amino-2-fluorophenyl)piperazine-1-carboxylate 
• 154590-34-8 4-(2-fluoro-4-nitrophenyl)-piperazine-1-carboxylic acid tert butyl ester 
• 369-34-6 3,4-difluoronitrobenzene 
• 1281885-22-0 3-fluoro-4-piperazin-1-yl-phenylamine dihydrochloride 
• 501-53-1 benzyl chloroformate 
• 212694-67-2 3-fluoro-4-(piperazin-1-yl)benzenamine 

Downstream Products

• 154590-66-6 (S)-N-[[3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 
• 1281885-30-0 (R)-benzyl 4-(2-fluoro-4-(2-oxo-5-(tosyloxymethyl)oxazolidin-3-yl)phenyl)piperazine-1-carboxylate 
• 239438-48-3 (R)-[N-3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl azide 
• 1282094-22-7 (S)-N-((3-(3-fluoro-4-(4-(3-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-7-yloxy)propyl)piperazin-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide hydrochloride 
• 1622399-55-6 (S)-N-((3-(3-fluoro-4-(4-(3-(4-(((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)methyl)-1H-1,2,3-triazol-1-yl)propyl)piperazin-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1622399-54-5 (S)-N-((1-(3-(4-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)propyl)-1H-1,2,3-triazol-4-yl)methyl)-2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamide 
• 1622399-53-4 (S)-N-((3-(3-fluoro-4-(4-(3-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)propyl)piper-azin-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1622399-52-3 (S)-N-((3-(3-fluoro-4-(4-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)piperazin-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1622399-51-2 (S)-N-((3-(4-(4-(3-azidopropyl)piperazin-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 903594-02-5 4-[2-Fluoro-4-((R)-5-methanesulfonyloxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-piperazine-1-carboxylic acid benzyl ester 
• 174649-08-2 N-((S)-3-{4-[4-(2-Benzyloxy-acetyl)-piperazin-1-yl]-3-fluoro-phenyl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide 
• 174649-06-0 (S)-N-[[3-[3-fluoro-4-[N-1-(4-carbobenzoxy)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 
• 198410-25-2 (S)-N-(3-(3-fluoro-4-((N-4-carbobenzoxy)piperazin-1-yl)phenyl)-2-oxo-oxazolidin-5-yl)methylamine 
• 165800-04-4 eperezolid 

Relevant articles and documents

An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants

An azide-functionalised analogue of the oxazolidinone antibiotic linezolid was synthesised and shown to retain antimicrobial activity. Using facile 'click' chemistry, this versatile intermediate can be further functionalised to explore antimicrobial structure-activity relationships or conjugated to fluorophores to generate fluorescent probes. Such probes can report bacteria and their location in a sample in real time. Modelling of the structures bound to the cognate 50S ribosome target demonstrates binding to the same site as linezolid is possible. The fluorescent probes were successfully used to image Gram-positive bacteria using confocal microscopy.

Discovery of a novel nitroimidazolyl-oxazolidinone hybrid with potent anti Gram-positive activity: Synthesis and antibacterial evaluation

A number of linezolid analogues containing a nitroaryl-1,3,4-thiadiazole moiety, were prepared and evaluated as antibacterial agents against a panel of Gram-positive and Gram-negative bacteria. Among synthesized compounds, nitrofuran analogue 1b exhibited more potent inhibitory activity, with respect to other synthesized compounds and reference drug linezolid. The target compounds were also assessed for their cytotoxic activity against normal mouse fibroblast (NIH/3T3) cells using MTT assay. The results indicated that compound 1c exhibit potent antibacterial activity against Gram-positive bacteria at non-cytotoxic concentrations.

BORON CONTAINING SMALL MOLECULES

This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Synthesis and antibacterial activities of eperezolid analogs with glycinyl substitutions

A series of eperezolid analogs with glycinyl substitutions were prepared and their antibacterial activities were studied against a panel of susceptible and resistant Gram-positive bacteria. The compounds with N-arylacyl or N-heteroarylacyl glycinyl struct

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.

Bacterial resistance development has become a very serious clinical problem for many classes of antibiotics. The 3-aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action which involves very early inhibition of bacterial protein synthesis. We have prepared two potent, synthetic oxazolidinones, U-100592 and U-100766, which are currently in clinical development for the treatment of serious multidrug-resistant Gram-positive bacterial infections caused by strains of staphylococci, streptococci, and enterococci. The in vitro and in vivo (po and iv) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin. U-100592 and U-100766 demonstrate potent in vitro activity against Mycobacterium tuberculosis. A novel and practical asymmetric synthesis of (5S)-(acetamidomethyl)-2-oxazolidinones has been developed and is employed for the synthesis of U-100592 and U-100766. This involves the reaction of N-lithioarylcarbamates with (R)-glycidyl butyrate, resulting in excellent yields and high enantiomeric purity of the intermediate (R)-5-(hydroxymethyl)-2-oxazolidinones.

Dynamic kinetic resolution of epichlorohydrin via enantioselective catalytic ring opening with TMSN3. Practical synthesis of aryl oxazolidinone antibacterial agents

The dynamic kinetic resolution of racemic epichlorohydrin has been achieved via enantioselective asymmetric ring opening with TMSN3 catalyzed by the (salen)Cr(III)N3 complex 1. The resulting 3-azido-1-chloro-2-trimethylsiloxypropane product was obtained in high enantiomeric purity and incorporated into the synthesis of U-100592, a representative from a class of highly-promising aryl oxazolidinone antibacterial agents.